lundi 19 juin 2017

Onco Actu du 19 juin 2017

1. Biologie

ER-beta For Breast Cancer: Think Again [In the Pipeline]

Researchers Gain Insight Into Cause of Infant & Treatment-Related Leukemias [Oncology Times]

2.5 Etiologie - Gènes

New concerns raised over value of genome-wide disease studies [Nature]

The GWAS hoax....or was it a hoax? Is it a hoax? [The Mermaid's Tale]

2.6 Etiologie - Environnement

Monsanto Spin Doctors Target Cancer Scientist In Flawed Reuters Story [Huffington Post]

4.12 Biopsies liquides

New three-in-one blood test opens door to precision medicine for prostate cancer [Institute of Cancer Research]

Prostate cancer blood test could transform treatment, say scientists [The Guardian]

New test may turn AZ's Lynparza into precision drug for prostate cancer [Reuters]

5. Traitements

Why treating breast cancer with less may be more [The Conversation]

5.12.1 Immunothérapies - partenariats

Billionaire-backed Parker Institute tackles the Holy Grail of cancer R&D — with a virtual unknown [EndPoints]

5.12.5 Immunothérapies - Pharma

Extended Follow-Up Data Evaluating Opdivo (nivolumab) Shows Durable Response in Adult Patients with Relapsed or Progressed Classical Hodgkin Lymphoma [BMS]

5.2 Pharma

Clovis Oncology's cancer drug Rubraca succeeds in key study [Reuters]

Clovis Oncology Rucaparib Significantly Improved Progression-Free Survival in All Ovarian Cancer Patient Populations Studied in Phase 3 ARIAL3 Maintenance Treatment Trial [Clovis]

5.2.1 Pharma - Partenariats

Merck KGaA taps Human Longevity to discover melanoma response biomarkers to MEK inhibitor following mixed data [FierceBiotech]

5.3 Traitements - FDA, EMA, NICE...

Sandoz receives approval in Europe for Rixathon® (biosimilar rituximab) to treat blood cancers and immunological diseases [Novartis]

Novartis throws down gauntlet to Roche with Rituxan copy [Reuters]

5.3.4 Traitements - AMM (FDA, EMA)

DARZALEX® (daratumumab) Approved by the U.S. FDA in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Who Have Received At Least Two Prior Therapies [Janssen]

5.4 Traitements - Economie

Breast cancer drug approved for NHS England [Cancer Research UK]

Gamechangers—who is playing, who is being played? [The Lancet USA Health Blog]

6.10.1 Politiques (USA)

White House Task Force Echoes Pharma Proposals [KHN]

6.5 Médecines alternatives

The sad but unexpectedly hopeful cancer saga of Cassandra Callender [Science-Based Medicine]

6.6 Publications

Biologists debate how to license preprints [Nature]

6.7 DMP, Big Data & applis

Barriers and facilitators to linking and sharing routine health data for research [PHG Foundation]